Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

Annals of the New York Academy of Sciences
Urte GaykoSen Hong Zhuang

Abstract

Ibrutinib is a first-in-class oral covalent inhibitor of Bruton's tyrosine kinase that has demonstrated clinical benefit for many patients with B cell malignancies. Positive results in initial trials led the U.S. Food and Drug Administration to grant ibrutinib three breakthrough therapy designations for mantle cell lymphoma (MCL), del17p chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia (WM). Ibrutinib was approved for these three cancers within 14 months of the original U.S. approval. Additionally, ibrutinib is approved for patient subsets with MCL and/or CLL in >45 other countries. Via a unique mechanism of action, ibrutinib inhibits B cell signaling pathways that regulate the survival, proliferation, adhesion, and homing of cancerous cells. This marks a paradigm shift from the conventional cytotoxic chemotherapy approach to treating B cell malignancies. Ibrutinib continues to be evaluated across a range of B cell malignancies, either as single-agent therapy or in combination with other therapies, and continues to transform the lives of these patients.

References

Jan 12, 2002·Developmental Immunology·A Maas, R W Hendriks
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosNikolaos Anagnostopoulos
Jul 1, 1964·Proceedings of the Society for Experimental Biology and Medicine·H A AZAR
Apr 2, 2005·Nature Reviews. Cancer·Ralf Küppers
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Dec 13, 2006·ChemMedChem·Zhengying PanJames T Palmer
Mar 14, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine I ChenUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Dec 17, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoyR I Fisher
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lee A HonigbergJoseph J Buggy
Nov 19, 2010·Expert Review of Hematology·Georg Hess
Jun 11, 2011·Critical Reviews in Oncology/hematology·Sergio CortelazzoMartin Dreyling
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Working Group
Sep 29, 2011·Seminars in Cancer Biology·Karin E Smedby, Henrik Hjalgrim
Nov 1, 2011·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Mariëlle W E BouwensSilvia Sanduleanu
Mar 24, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wasif N Khan
Mar 28, 2012·International Reviews of Immunology·Joseph J Buggy, Laurence Elias
Jun 13, 2012·Best Practice & Research. Clinical Haematology·Jonathan W Friedberg
Aug 31, 2012·The New England Journal of Medicine·Steven P TreonZachary R Hunter
Sep 22, 2012·British Journal of Haematology·P McKayUNKNOWN British Committee for Standards in Haematology
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique LeblondRoger G Owen
Jan 9, 2013·Current Hematologic Malignancy Reports·Jennifer R Brown
Feb 22, 2013·Leukemia & Lymphoma·Jan A Burger, Joseph J Buggy
Mar 2, 2013·Nature Reviews. Drug Discovery·Ryan M Young, Louis M Staudt
Apr 16, 2013·European Journal of Internal Medicine·Chiara Lobetti-BodoniEmanuele Zucca
May 10, 2013·Leukemia & Lymphoma·Jennifer R Brown
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyThomas E Witzig
Sep 10, 2013·Advances in Experimental Medicine and Biology·Jan A Burger
Dec 18, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitchell R Smith
Mar 25, 2014·Nature Reviews. Cancer·Rudi W HendriksLaurens P Kil
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Apr 9, 2015·The New England Journal of Medicine·Steven P TreonRanjana H Advani

❮ Previous
Next ❯

Citations

Dec 6, 2016·Lancet·Syed S MahmoodJennifer Leaning
Aug 10, 2016·Molecular & Cellular Proteomics : MCP·Joel D FederspielDaniel C Liebler
Mar 22, 2018·NPJ Systems Biology and Applications·Rajiv Gandhi GovindarajMichal Brylinski
Feb 2, 2019·Archives of Pharmacal Research·Hyung-Ook Kim
Apr 17, 2019·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Deepesh P LadSubhash Varma
May 6, 2021·The American Journal of the Medical Sciences·Liuyue XuXiaoqiong Tang
Nov 15, 2020·Cancer Treatment and Research Communications·Michael SchafferSriram Balasubramanian
Dec 19, 2016·Chemical Research in Toxicology·Jinping GanW Griffith Humphreys

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.